Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus
- 1 February 2021
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (11), 2979-2988
- https://doi.org/10.1158/1078-0432.ccr-20-1565
Abstract
Cancer immunotherapy targeting immune checkpoint inhibitors shows efficacy in several human cancers, but “cold tumors” that lack immune cells are typically unresponsive. Among the potential therapeutic approaches that could “heat” or promote lymphocyte infiltration of cold tumors, oncolytic viruses have attracted interest for their lytic and immunogenic mechanisms of action. In this article, we review the use of oncolytic adenoviruses in cancer immunotherapy, with a particular focus on preclinical and clinical data of oncolytic adenovirus-triggered immune responses against tumor antigens. We also discuss parameters to consider in clinical trial design and the combination of oncolytic adenoviruses with conventional treatments or other immunotherapies.Keywords
Funding Information
- Ministerio de Ciencia e Innovación (BIO2017-89754-C2-1-R)
- Generalitat de Catalunya (2017SGR449, 2015 DI 0070)
- AGAUR
- European Regional Development Fund
This publication has 80 references indexed in Scilit:
- A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder CancerJournal of Urology, 2012
- Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4Gene Therapy, 2011
- Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic AdenovirusMolecular Therapy, 2011
- Minimal RB-responsive E1A Promoter Modification to Attain Potency, Selectivity, and Transgene-arming Capacity in Oncolytic AdenovirusesMolecular Therapy, 2010
- Ligand-Independent Toll-like Receptor Signals Generated by Ectopic Overexpression of MyD88 Generate Local and Systemic Antitumor ImmunityCancer Research, 2010
- The Immunogenicity of Adenovirus Vectors Limits the Multispecificity of CD8 T-cell Responses to Vector-encoded Transgenic AntigensMolecular Therapy, 2008
- Factors influencing retention of adenovirus within tumours following direct intratumoural injectionGene Therapy, 2008
- Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulationOncogene, 2007
- A Tumor-Targeted and Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL for Treatment of Liver MetastasesMolecular Therapy, 2004
- Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of Phase I and II trialsExpert Opinion on Biological Therapy, 2001